<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276757</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454768</org_study_id>
    <secondary_id>HISTSOC-LCH-III</secondary_id>
    <secondary_id>CCLG-LCH-III</secondary_id>
    <secondary_id>EU-20587</secondary_id>
    <secondary_id>CCLG-LCH-2002-07</secondary_id>
    <secondary_id>UMN-2006NT004</secondary_id>
    <nct_id>NCT00276757</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis</brief_title>
  <official_title>Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Histiocyte Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of Langerhans&#xD;
      cell histiocytosis, either by killing the cells or by stopping them from dividing. Giving&#xD;
      more than one drug (combination chemotherapy) may be an effective treatment for Langerhans&#xD;
      cell histiocytosis.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying combination chemotherapy to see how well&#xD;
      it works in treating young patients with Langerhans cell histiocytosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the efficacy, in terms of response to initial therapy, of prednisolone,&#xD;
           vinblastine, and mercaptopurine with vs without methotrexate and leucovorin calcium in&#xD;
           young patients with Langerhans cell histiocytosis.&#xD;
&#xD;
        -  Compare the progression-free survival of patients with low-risk Langerhans cell&#xD;
           histiocytosis who responded to initial therapy who are then treated with 6-month vs&#xD;
           12-month continuation therapy comprising prednisolone and vinblastine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the acute and long-term toxicity and the incidence of permanent effects.&#xD;
&#xD;
        -  Compare the overall and progression-free survival, response rate, and time until&#xD;
           response.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study with one pilot nonrandomized stratum.&#xD;
      Patients are stratified according to number of systems involved (multiple vs single) and&#xD;
      organs involved (at risk vs low risk).&#xD;
&#xD;
        -  Stratum 1 (at risk patients): Patients are further stratified according to participating&#xD;
           center. Patients are randomized to 1 of 2 treatment arms (arms I and II).&#xD;
&#xD;
             -  Arm I:&#xD;
&#xD;
                  -  Initial therapy: Patients receive oral prednisolone 3 times daily on days 1-28&#xD;
                     followed by a taper on days 29-42 and vinblastine IV on days 1, 8, 15, 22, 29,&#xD;
                     and 36. Patients achieving nonactive disease (NAD) after course 1 proceed to&#xD;
                     continuation therapy. Patients achieving intermediate response or disease&#xD;
                     regression receive a second course* of initial therapy. Patients achieving NAD&#xD;
                     or disease regression after course 2 proceed to continuation therapy.&#xD;
&#xD;
                  -  Continuation therapy: Patients receive oral mercaptopurine daily for 3 weeks,&#xD;
                     pulsed oral prednisolone 3 times daily on days 1-5, and vinblastine IV on day&#xD;
                     1. Treatment repeats every 3 weeks until day 365 from the beginning of therapy&#xD;
                     in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Arm II:&#xD;
&#xD;
                  -  Initial therapy: Patients receive prednisone and vinblastine as in arm I&#xD;
                     initial therapy. Patients also receive methotrexate IV over 24 hours on days&#xD;
                     1, 15, and 29 and oral leucovorin calcium twice daily on days 2,16, and 30.&#xD;
                     Patients achieving NAD after course 1 proceed to continuation therapy.&#xD;
                     Patients achieving intermediate response or disease regression receive a&#xD;
                     second course* of initial therapy. Patients achieving NAD or disease&#xD;
                     regression after course 2 proceed to continuation therapy.&#xD;
&#xD;
                  -  Continuation therapy: Patients receive oral mercaptopurine daily for 3 weeks,&#xD;
                     pulsed oral prednisolone 3 times daily on days 1-5, vinblastine IV on day 1,&#xD;
                     and oral methotrexate on day 1. Treatment repeats every 3 weeks until day 365&#xD;
                     from the beginning of therapy in the absence of disease progression or&#xD;
                     unacceptable toxicity.&#xD;
&#xD;
        -  Stratum 2 (low-risk patients): Patients are stratified according to age at diagnosis (â‰¤&#xD;
           2 vs &gt; 2) and participating center. Patients are randomized to 1 of 2 treatment arms&#xD;
           (arms III and IV) after the first course of initial therapy.&#xD;
&#xD;
             -  Arm III:&#xD;
&#xD;
                  -  Initial therapy: Patients receive prednisolone and vinblastine as in course 1&#xD;
                     of stratum 1 arm I initial therapy. Patients achieving NAD or disease&#xD;
                     regression after course 1 proceed to continuation therapy. Patients achieving&#xD;
                     intermediate or worse response receive a second course* of initial therapy.&#xD;
                     Patients achieving NAD, disease regression, or intermediate response after&#xD;
                     course 2 proceed to continuation therapy.&#xD;
&#xD;
                  -  Continuation therapy: Patients receive prednisolone and vinblastine as in&#xD;
                     stratum 1 arm I continuation therapy. Treatment continues until day 182 from&#xD;
                     the beginning of initial therapy in the absence of disease progression or&#xD;
                     unacceptable toxicity.&#xD;
&#xD;
             -  Arm IV:&#xD;
&#xD;
                  -  Initial therapy: Patients receive 1-2 courses of prednisolone and vinblastine&#xD;
                     as in stratum 2 arm III.&#xD;
&#xD;
                  -  Continuation therapy: Patients receive pulsed prednisolone and vinblastine as&#xD;
                     in stratum 1 arm I continuation therapy. Treatment continues until day 365&#xD;
                     from the beginning of initial therapy in the absence of disease progression or&#xD;
                     unacceptable toxicity.&#xD;
&#xD;
        -  Stratum 3 (pilot study) (patients with multifocal bone disease and/or special sites):&#xD;
&#xD;
             -  Initial therapy: Patients receive prednisolone and vinblastine as in stratum 1 arm&#xD;
                I initial therapy. Patients achieving NAD or disease regression after course 1&#xD;
                proceed to continuation therapy. Patients with disease progression receive a second&#xD;
                course* of initial therapy. Patients achieving NAD or disease regression after&#xD;
                course 2 proceed to continuation therapy.&#xD;
&#xD;
             -  Continuation therapy: Patients receive pulsed prednisolone and vinblastine as in&#xD;
                stratum 1 arm I continuation therapy. Treatment continues until day 182 from the&#xD;
                beginning of initial therapy in the absence of disease progression or unacceptable&#xD;
                disease.&#xD;
&#xD;
      NOTE: *Patients receive oral prednisolone 3 times daily on days 43-45, 50-52, 57-59, 64-66,&#xD;
      71-73, and 78-80 only during the second course of initial therapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 376 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Childhood Langerhans Cell Histiocytosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histopathologically confirmed diagnosis of Langerhans cell histiocytosis according to&#xD;
             the criteria defined by the Histiocyte Society&#xD;
&#xD;
               -  Demonstration of CD1a antigenic determinants on the surface of lesional cells (by&#xD;
                  immunocytology or immunohistology) or Birbeck granules in lesional cells by&#xD;
                  electron microscopy&#xD;
&#xD;
          -  Considered at risk or low risk according to the following criteria:&#xD;
&#xD;
               -  Multi-system at risk disease, defined as involvement of one or more risk organs&#xD;
                  (i.e., hematopoietic system, liver, spleen, or lungs)&#xD;
&#xD;
                    -  No single-system lung involvement&#xD;
&#xD;
               -  Multi-system low-risk disease&#xD;
&#xD;
                    -  Multiple organs involved but without involvement of risk organs&#xD;
&#xD;
               -  Single-system disease&#xD;
&#xD;
                    -  Multifocal bone disease (i.e., lesions in 2 or more different bones)&#xD;
&#xD;
                    -  Localized special site involvement, such as CNS-risk lesions with&#xD;
                       intracranial soft tissue extension or vertebral lesions with intraspinal&#xD;
                       soft tissue extension&#xD;
&#xD;
                         -  Vault lesions are not regarded as CNS-risk lesions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior treatment for Langerhans cell histiocytosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth L. McClain, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Texas Children's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-9700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Pediatria Garrahan</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1245</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione I.R.C.C.S. Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Cancer and Leukaemia Group</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 6TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>childhood Langerhans cell histiocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

